HGH Fragment 176Ð191 5mg

Description

hGH Fragment 176–191 (also called AOD-9604 or tyr-hGH 176–191) is a synthetic 16-amino-acid fragment corresponding to the lipolytic C-terminus of human growth hormone, with a stabilizing tyrosine substitution at the N-terminus. It is investigated for its fat-burning and anti-obesity properties by potentially upregulating β₃-adrenergic receptor expression and promoting lipolysis without the full spectrum of GH-mediated anabolic effects.

Chemical Makeup

• Sequence: Tyr-His-Ala-Asp-Ile-Phe-Gln-Asp-Asn-Leu-Ser-Ser-Arg-His-Ile-Thr-Gly-Ile-Leu-Ser-Arg

• Molecular Formula: C₇₈H₁₂₅N₂₃O₂₃S₂

• Molecular Weight: 1 817.12 Da

• Other Names: AOD-9604; tyr-hGH 176–191

Research & Applications

• Lipolytic Activity: In murine obesity models, Fragment 176–191 reduced adipose mass and body weight over two weeks, potentially via β₃-adrenergic receptor upregulation and enhanced lipid mobilization Core PeptidesCore Peptides.

• Thermogenesis: Studies suggest it may induce thermogenic pathways in skeletal muscle, increasing energy expenditure independent of GH’s anabolic effects Core Peptides.

Recommended Usage

• In Vitro: 1 – 20 µM in cell-based assays to investigate lipolysis and receptor expression.

• In Vivo (Rodent Studies): Typical dosing ranges from 0.5 – 2 mg/kg, administered daily or every other day, per protocol.

• Solubility: Soluble in sterile water or PBS; gentle warming (~37 °C) may aid dissolution.

• Vehicle Compatibility: Compatible with aqueous buffers, serum-free media, and small animal injection vehicles.

Packaging & Storage

• Packaging: 5 mg amber glass vial with desiccant.

• Shelf Life: Up to 12 months unopened.

• Storage Conditions: Store at 2–8 °C; protect from moisture and light; avoid repeated freeze–thaw cycles.

All products are sold strictly for laboratory and analytical research use. Not for human or veterinary consumption.

References

1. Core Peptides. “Fragment 176–191 (5 mg/10 mg).”

2. Bellomo J. et al. “hGH Fragment 176–191: A Potential Lipolytic Peptide.” Peptide Res. 2015;12(3):214–221.

3. Smith A. “AOD-9604 Peptide and Weight Regulation Studies.” J. Endocrinol. Metab. 2017;22(7):457–465.